Results released
Open the filing on sec.gov
Dyne Therapeutics, Inc. (DYN)
Nasdaq: DYN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
The companyfiscal 2025, as filed
Revenuen/a
Net income-$446M-40.6%
Earnings per share$-3.47-3.0%
Operating cash flow-$403M-37.9%
Cash$893M+105.2%
Debt$149M
Shareholders’ equity$972M+54.3%
Shares, dilutedn/a
Return on equity-45.9%
The recordfrom its filings
Filings in 2026176
Newest filingNov 5 · 8-K
Annual reportMar 2, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$169M
Insider buys, 12 months$300,000
Patents granted54
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Net income -$605MCash from operations -$565Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.